Centessa Insider Plans 10,000-Share CNTA Sale Worth $140K

Centessa Pharmaceuticals (NASDAQ: CNTA) submitted a Form 144 notice covering the proposed sale of 10,000 common shares—approximately $140,000 in aggregate market value—through UBS Financial Services on or around 26 June 2025.

Rhea-AI Filing Summary

Centessa Pharmaceuticals (NASDAQ: CNTA) submitted a Form 144 notice covering the proposed sale of 10,000 common shares—approximately $140,000 in aggregate market value—through UBS Financial Services on or around 26 June 2025. The filing lists 133,618,774 shares outstanding, so the planned sale represents less than 0.01 % of the float.

The same account holder reported three earlier open‐market sales during the past three months: 10,000 shares on 25 March 2025 for $163,386, 11,742 shares on 25 April 2025 for $159,857, and 10,000 shares on 27 May 2025 for $128,225. Combined with the new notice, gross proceeds from the four transactions total roughly $591,000. No additional financial statements, risk factors, or business updates were provided in this routine disclosure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Centessa (CNTA) shares are covered by the new Form 144 filing?

The notice covers 10,000 common shares with an estimated market value of about $140,000.

What percentage of Centessa’s outstanding shares does the proposed 10,000-share sale represent?

With 133,618,774 shares outstanding, the sale represents less than 0.01 % of total shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2025 - 04:06 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001400975
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Centessa Pharmaceuticals plc
SEC File Number	001-40445
Address of Issuer	3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE UNITED KINGDOM WA14 2DT
Phone	44 7391 789784
Name of Person for Whose Account the Securities are To Be Sold	Weinhoff Gregory M
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	10000	140000.00	133618774	06/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/25/2025	Exercise of Stock Options	Issuer			10000	06/25/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Gregory Weinhoff 3rd Floor 1 Ashley Road Altrincham, Cheshire X0 WA14 2DT	Common	05/27/2025	10000	128225.00
Gregory Weinhoff 3rd Floor 1 Ashley Road Altrincham, Cheshire X0 WA142DT	Common	03/25/2025	10000	163386.00
Gregory Weinhofff 3rd Floor, 1 Ashley Road Altrincham X0 X0 WA142DT	Common	04/25/2025	11742	159856.76

144: Remarks and Signature

Remarks	The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.
Date of Notice	06/25/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Gregory Weinhoff
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)